Evoke Pharma, Inc. (NASDAQ:EVOK) Sees Large Decrease in Short Interest

Evoke Pharma, Inc. (NASDAQ:EVOK) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 11,300 shares, a decrease of 54.4% from the June 15th total of 24,800 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 27,500 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Evoke Pharma in a report on Sunday, July 7th. They set a “sell” rating on the stock.

Evoke Pharma Stock Up 1.8 %

EVOK stock traded up $0.01 during trading on Friday, reaching $0.58. 20,438 shares of the company were exchanged, compared to its average volume of 43,801. The stock’s 50 day moving average price is $0.50 and its 200 day moving average price is $0.62. Evoke Pharma has a 52-week low of $0.40 and a 52-week high of $1.77.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter. The firm had revenue of $1.74 million during the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.